ProfileGDS5678 / 1447926_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 72% 73% 77% 74% 75% 75% 76% 72% 75% 73% 73% 73% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7881274
GSM967853U87-EV human glioblastoma xenograft - Control 24.6349672
GSM967854U87-EV human glioblastoma xenograft - Control 34.6842673
GSM967855U87-EV human glioblastoma xenograft - Control 45.4317577
GSM967856U87-EV human glioblastoma xenograft - Control 54.8174574
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8304775
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8322875
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.1236576
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6301172
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9275475
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.693873
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7586573
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6867973
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5234872